Clinical Trials Logo
  1. Home
  2. Tinea Cruris
  3. NCT00750152

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris

Tinea Cruris Clinical Trial

Official title:
A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris

Clinical Trial Summary

A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.

Clinical Trial Description

To evaluate the efficacy and safety of NAFT-500, applied once daily for 2 weeks, compared to placebo in the treatment of subjects with potassium hydroxide (KOH) and culture positive symptomatic tinea cruris. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00750152
Study type Interventional
Source Merz Pharmaceuticals, LLC
Contact
Status Completed
Phase Phase 3
Start date September 2008
Completion date February 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT01712360 - Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Phase 4
Not yet recruiting NCT05881980 - Efficacy and Safety of Terbinafine and Itraconazole Phase 2/Phase 3
Completed NCT01349998 - Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Phase 3
Completed NCT01342315 - Topical Antifungal Treatment for Tinea Cruris Phase 3
Completed NCT03359070 - Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris Phase 2
Completed NCT02394340 - Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris Phase 4
Completed NCT05363449 - Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis Phase 1
Completed NCT02767271 - Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris Phase 4
Completed NCT01885156 - Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Phase 3
Not yet recruiting NCT01105013 - Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Phase 3